Surgery Partners, Inc.

As of October 24, 2025, Surgery Partners, Inc. has a mildly bearish trend influenced by mixed technical indicators, outperforming the S&P 500 recently but significantly underperforming over the long term.

As of October 24, 2025, Surgery Partners, Inc. shows a mildly bearish trend with mixed signals across various indicators, including bearish MACD and KST readings, while Bollinger Bands present a bullish outlook on the weekly timeframe.

As of October 24, 2025, Surgery Partners, Inc. shows a mildly bearish trend with mixed technical indicators, including a bearish weekly MACD and a mildly bullish monthly MACD, while outperforming the S&P 500 recently but underperforming over the past year.

As of October 3, 2025, Surgery Partners, Inc. is in a mildly bearish trend, indicated by bearish signals in MACD and Bollinger Bands, despite a mildly bullish KST signal, and has significantly underperformed the S&P 500 with a 1-year return of -34.56%.

As of October 3, 2025, Surgery Partners, Inc. exhibits a mildly bearish technical trend, with conflicting indicators across different time frames and a significant underperformance compared to the S&P 500.

As of October 3, 2025, Surgery Partners, Inc. has a mildly bearish trend, indicated by bearish MACD and moving averages, with a 1-year return of -32.19% compared to the S&P 500's 17.82%.

As of September 10, 2025, Surgery Partners, Inc. has a bearish technical trend with weak strength, indicated by bearish daily moving averages and monthly MACD, while the stock has declined 31.50% over the past year, underperforming the S&P 500's 17.14% gain.

As of August 6, 2024, Surgery Partners, Inc. is considered a risky investment due to its overvaluation indicated by a high P/E ratio of 39 compared to the peer average of 31.47, a lower ROE of 4.40% than the industry average, and significant underperformance against the S&P 500.

As of August 6, 2024, Surgery Partners, Inc. is considered overvalued with a high P/E ratio of 39 and low ROE of 4.40%, significantly lagging behind industry peers and the S&P 500, leading to a shift in its valuation grade from very attractive to risky.

As of June 17, 2025, Surgery Partners, Inc. is in a bearish trend, indicated by negative MACD readings, a bearish moving average, and underperformance against the S&P 500.

As of March 2022, the management team of Surgery Partners, Inc. includes Executive Chairman Wayne DeVeydt, CEO J. Eric Evans, and several independent directors: Clifford Adlerz, John Deane, Teresa DeLuca, Andrew Kaplan, and T. Devin O'Reilly. They oversee the company's operations and strategic direction.

Surgery Partners, Inc. is a small-cap healthcare services company in the hospital industry, with recent net sales of $776 million and a market cap of approximately $2.61 billion. Key financial metrics include a P/E ratio of 39.00 and a debt-to-equity ratio of 1.43.

As of Jun 18, Surgery Partners, Inc. has a market capitalization of $2.61 billion, with net sales of $3.17 billion and a net profit of -$12.1 million over the last four quarters.